Nuclear Medicine and Biology
短名 | Nucl. Med. Biol. |
Journal Impact | 3.63 |
国际分区 | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING(Q1) |
期刊索引 | SCI Q2中科院 4 区 |
ISSN | 0969-8051, 1872-9614 |
h-index | 98 |
国内分区 | 医学(4区)医学核医学(4区) |
核医学和生物学发表了涉及放射性药物科学各个方面的原创研究:合成、体外和离体研究、通过解剖或成像进行的体内生物分布、放射性药理学、放射性药物学和新靶向放射性示踪剂的转化临床研究。应首先考虑目标对未满足临床需求的重要性。如果在没有体外或体内数据的情况下提交新放射性药物的合成,则必须强调化学的独特性。这些多学科研究应验证探针是否基于与受体、酶、肿瘤结合的定位机制抗原,或另一个明确定义的目标。研究应旨在评估化学和放射性药物特性如何影响药代动力学、药效学或治疗效果。理想情况下,该研究将解决探针对疾病或治疗变化的敏感性,尽管单独验证机制的研究是可以接受的。放射性药物实践,解决制备、自动化、质量控制、分配和适用于人类放射性药物资格和管理的法规问题,是发展过程的一个重要方面,但前提是该研究对该领域有重大影响。如果标记化合物定位的特异性和治疗效果已经得到解决,那么对治疗性放射性药物主题的贡献也是适当的。
期刊主页投稿网址涉及主题 | 化学生物医学遗传学生物化学内科学生物技术体内有机化学物理体外心理学核医学内分泌学神经科学放射科受体材料科学体内分布药理学放射化学 |
出版信息 | 出版商: Elsevier Inc.,出版周期: Bimonthly,期刊类型: journal |
基本数据 | 创刊年份: 1986,原创研究文献占比: 98.31%,自引率:5.60%, Gold OA占比: 35.59% |
平均审稿周期 | 网友分享经验:一般,3-8周来源Elsevier官网:平均8周 |
平均录用比例 | 网友分享经验:容易 |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Production, purification and formulation of Nanoradiopharmaceutical with 211At: An emerging candidate for targeted alpha therapy
2024-11-1
Structure-affinity-pharmacokinetics relationships of 111In-labeled PSMA-targeted ligands with different albumin binders
2024-11-1
Preclinical investigation of the effect of stress on the binding of [18F]F13640, a 5-HT1A radiopharmaceutical
2024-11-1
Preclinical evaluation of [225Ac]Ac-crown-TATE – An alpha-emitting radiopharmaceutical for neuroendocrine tumors
2024-11-1
Automation of simplified two-step radiolabeling via ditosylate synthon for 18F-labeled radiotracers using AllinOne module
2024-9-1
Towards imaging the immune state of cancer by PET: Targeting legumain with 11C-labeled P1-Asn peptidomimetics carrying a cyano-warhead
2024-9-1
Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen
2024-9-1
The importance of radiochemical purity: Cellular binding and internalization of different radiometal chlorides in prostate cancer cells
2024-9-1
Evaluation of heterotopic ossification maturity using SPECT/CT and PET/CT in preclinical model
2024-9-1
[89Zr]ZrCl4 for direct radiolabeling of DOTA-based precursors
2024-9-1
Synthesis and characterization of 64Cu-labeled Geldanamycin derivative for imaging HSP90 expression in breast cancer
2024-9-1
Actinium-225 photonuclear production in nuclear reactors using a mixed radium-226 and gadolinium-157 target
2024-9-1
An electrochemical generator for the continual supply of 213Bi from 225Ac for use in targeted alpha therapy applications
2024-9-1
Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-αMSH and [161Tb]Tb-crown-αMSH
2024-9-1
Synthesis and preclinical evaluation of [18F]AlF-NODA-MP-C6-CTHRSSVVC as a PET tracer for CD163-positive tumor-infiltrating macrophages
2024-8-10
Transcatheter pseudo-vascular isolation for localization and concentration of a large molecule theranostic probe into a transgenic OncoPIG kidney tumor
2024-7-3
Editorial Board
2024-7-1
Outside Back Cover - Graphical abstract TOC/TOC in double column/Cover image legend if applicable, Bar code, Abstracting and Indexing information
2024-7-1
[18F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response
2024-7-1
A third generation PSMA-targeted agent [211At]YF2: Synthesis and in vivo evaluation
2024-7-1
Study of activation cross sections of double neutron capture reaction on 193Ir for the reactor production route of radiotherapeutic 195mPt
2024-7-1
Combining poly-epitope MoonTags and labeled nanobodies for signal amplification in cell-specific PET imaging in vivo
2024-6-20
Target engagement of an anti-MT1-MMP antibody for triple-negative breast cancer PET imaging and beta therapy
2024-5-23
Tracking the fate of bacteria-derived site-specific immunomodulators by positron emission tomography
2024-5-1
Editorial Board
2024-5-1
Reduction of the hepatic radioactivity levels of [111In]In-DOTA–labeled antibodies via cleavage of a linkage metabolized in lysosomes
2024-5-1
Outside Back Cover - Graphical abstract TOC/TOC in double column/Cover image legend if applicable, Bar code, Abstracting and Indexing information
2024-5-1
Initial insights into the interaction of antibodies radiolabeled with Lutetium-177 and Actinium-225 with tumor microenvironment in experimental human and canine osteosarcoma
2024-5-1
Development of 225Ac/213Bi generator based on α-ZrP-PAN composite for targeted alpha therapy
2024-5-1
Synthesis and evaluation of novel trifunctional chelating agents for pretargeting approach using albumin binder to improve tumor accumulation
2024-5-1
Application of copper (I) selective ligands for PET imaging of reactive oxygen species through metabolic trapping
2024-4-1
PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics
2024-4-1
Chemokine receptor PET imaging: Bridging molecular insights with clinical applications
2024-4-1
Synthesis and evaluation of a 68Ga-labeled spermine derivative for tumor PET imaging
2024-4-1
The future of the radiopharmaceutical sciences
2024-3-27
Second generation Al18F-labeled D-amino acid peptide for CXCR4 targeted molecular imaging
2024-3-19
Investigation of imaging the somatostatin receptor by opening the blood-brain barrier with melittin – A feasibility study using positron emission tomography and [64Cu]Cu-DOTATATE
2024-3-19
Evaluation of acute intravenous toxicity of HEPES: Is Good's buffer good and safe enough for clinical utilization in nuclear medicine?
2024-3-9
Outside Back Cover - Graphical abstract TOC/TOC in double column/Cover image legend if applicable, Bar code, Abstracting and Indexing information
2024-3-1
Improved purification of cyclotron [68Ga]GaCl3 for the production of 68Ga radiopharmaceuticals
2024-3-1
Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases
2024-3-1
Editorial Board
2024-3-1
Development of a CCR2 targeted 18F-labeled radiotracer for atherosclerosis imaging with PET
2024-3-1
Serotonin transporter imaging agent as a probe for β-cells of pancreas
2024-3-1
In vitro evaluation of [3H]PI-2620 and structural derivatives in non-Alzheimer's tauopathies
2024-3-1
Biodistribution study of 211Pb progeny released from intravenously applied 223Ra labelled TiO2 nanoparticles in a mouse model
2024-2-1
Evaluation of targeting αVβ3 in breast cancers using RGD peptide-based agents
2024-2-1
Editorial Board
2024-1-1
Evaluation of a novel hexadentate 1,2-hydroxypyridinone-based acyclic chelate, HOPO-O6-C4, for 43Sc/47Sc, 68Ga, and 45Ti radiopharmaceuticals
2024-1-1
Evaluation of F-537-Tetrazine in a model for brain pretargeting imaging. Comparison to N-(3-[18F] fluoro-5-(1,2,4,5-tetrazin-3-yl)benzyl)propan-1-amine
2024-1-1
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远